Grifols (NASDAQ:GRFS) Stock Rating Raised to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Grifols (NASDAQ:GRFS) from a hold rating to a buy rating in a research note released on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also issued research reports about the company. Weiss Ratings upgraded Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. decreased their price target on Grifols from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Monday, October 26th. Finally, Zacks Research downgraded Grifols from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 3rd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $9.00.

Grifols Trading Down 1.3%

Shares of GRFS traded down $0.11 during mid-day trading on Friday, reaching $8.69. The stock had a trading volume of 312,712 shares, compared to its average volume of 827,725. The business has a fifty day moving average of $7.75 and a 200 day moving average of $7.99. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.82 and a current ratio of 2.33. Grifols has a 12 month low of $6.96 and a 12 month high of $9.77.

Grifols Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Monday, January 11th. Stockholders of record on Thursday, December 3rd will be given a dividend of $0.1686 per share. The ex-dividend date is Thursday, December 3rd. This represents a dividend yield of 385.0%.

Institutional Investors Weigh In On Grifols

Several large investors have recently made changes to their positions in GRFS. Flat Footed LLC increased its position in shares of Grifols by 26.5% during the 1st quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after purchasing an additional 287,867 shares during the last quarter. Tidal Investments LLC raised its holdings in Grifols by 9.8% during the 2nd quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock valued at $8,730,000 after buying an additional 109,612 shares during the period. Royal Bank of Canada raised its holdings in Grifols by 15.4% during the 1st quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock valued at $6,301,000 after buying an additional 104,850 shares during the period. Quantinno Capital Management LP raised its holdings in Grifols by 42.0% during the 1st quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock valued at $2,829,000 after buying an additional 104,418 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its position in Grifols by 13.8% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock worth $4,193,000 after buying an additional 72,037 shares during the last quarter.

Grifols Company Profile

Grifols is a global healthcare company headquartered in Barcelona, Spain, focused on developing and producing plasma-derived medicines and other healthcare products. Founded in 1909, the company has expanded from its origins in laboratory services into a business spanning plasma collection, biopharmaceuticals, diagnostics and hospital solutions. Its biopharmaceutical business collects and processes human plasma to make medicines, including immunoglobulins, albumin and coagulation factors. Grifols also supplies diagnostic products and services for transfusion medicine and offers products used in hospitals and clinical laboratories.